N
KROS icon

Natixis’s Keros Therapeutics KROS Stock Holding History

Natixis’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.1K Buy
+100
New +$1.54K ﹤0.01% 1063

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Natixis's KROS Position: Q1 2026 in Review

Natixis opened a new position in Keros Therapeutics (KROS) in Q1 2026: 100 shares worth $1.1K. The stake represents ﹤0.01% of the portfolio and ranks #1063 among its holdings.

151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Natixis held 100 shares of Keros Therapeutics worth $1.1K as of Q1 2026.
  • Keros Therapeutics was a new Natixis position in Q1 2026.
  • Keros Therapeutics made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #1063 holding.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.